SG
BMY.RT

StoneX Group’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

StoneX Group’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-18,885
Closed -$13K – 446
2020
Q4 		$13K Hold
18,885
– – ﹤0.01% 365
2020
Q3 		$42K Hold
18,885
– – 0.01% 327
2020
Q2 		$68K Sell
18,885
-75
-0.4% -$271 0.03% 291
2020
Q1 		$72K Sell
18,960
-600
-3% -$1.98K 0.04% 245
2019
Q4 		$59K Buy
+19,560
New +$50.9K 0.02% 299

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

StoneX Group's BMY.RT Position: Q1 2021 in Review

StoneX Group sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 18,885 shares — an estimated $13K sold.

StoneX Group first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $72K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • StoneX Group reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • StoneX Group sold 18,885 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $13K.
  • StoneX Group first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • StoneX Group's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $72K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on StoneX Group's 13F filing for Q1 2021, filed 23 Jun 2021.